On October 26, 2020 Theralase Technologies Inc. ("Theralase" or the "Company")(TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and associated drug formulations reported that it has released the Company Quarterly Newsletter (Press release, Theralase, OCT 26, 2020, View Source [SID1234569761]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Newsletter provides updates on the previous quarter and progress on the Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study.
The Newsletter can be found on the Company’s website www.theralase.com/quarterly-newsletters/.